Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes


Research output: Contribution to journalArticlepeer-review


AIMS: The aim of this study was to investigate the effect of ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT) or conventional DAPT in patients with or without acute coronary syndrome (ACS) in the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).

METHODS AND RESULTS: Risk estimates were expressed as rate ratios (RR) with 95% confidence intervals (CI). A total of 3,840 ACS and 3,745 stable ischaemic heart disease (SIHD) patients were included. At two years, rates of the co-primary efficacy endpoint, a composite of death, myocardial infarction, stroke or urgent target vessel revascularisation, were 7.94% in the experimental and 9.68% in the control group (RR 0.82, 95% CI: 0.66-1.01) among ACS patients and 6.31% in the experimental and 7.14% in the control group (RR 0.89, 95% CI: 0.69-1.13) among SIHD patients (pint=0.63). Trends for lower and higher risk of BARC 3 or 5 bleeding with the experimental strategy in ACS (2.27% vs 3.00%, RR 0.76, 95% CI: 0.51-1.12) and SIHD (2.70% vs 1.96%, RR 1.39, 95% CI: 0.91-2.12) patients, respectively, were observed with significant interaction testing (pint=0.039). A net clinical benefit endpoint, the composite of both co-primary study endpoints, favoured the experimental treatment among ACS patients only.

CONCLUSIONS: Ticagrelor monotherapy after one-month DAPT provided consistent treatment effects on ischaemic endpoints in patients with or without ACS but only the former experienced a net clinical benefit. ClinicalTrials.gov identifier: NCT03231059.

Original languageEnglish
Pages (from-to)627-633
Number of pages7
Issue number8
Publication statusPublished - Oct 23 2020


  • Acute Coronary Syndrome/drug therapy
  • Aspirin/therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors/therapeutic use
  • Ticagrelor/adverse effects
  • Treatment Outcome


Dive into the research topics of 'Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes'. Together they form a unique fingerprint.

Cite this